Subscribe To
MLYS / Mineralys Therapeutics Builds On Phase 2 Trial Success With IPO Filing
MLYS News
By Zacks Investment Research
September 5, 2023
Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 199.3% upside in the stock. While this highly sought-after met more_horizontal
By Zacks Investment Research
August 22, 2023
Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Mineralys Therapeutics, Inc. (MLYS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with stro more_horizontal
By Seeking Alpha
August 12, 2023
Mineralys Therapeutics, Inc. (MLYS) Q2 2023 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisor more_horizontal
By GlobeNewsWire
July 31, 2023
Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023
RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on deve more_horizontal
By GlobeNewsWire
May 1, 2023
Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023
RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on devel more_horizontal
By Seeking Alpha
April 21, 2023
Mineralys: New IPO And A Leader In The Hypertension Drug Development Space
Mineralys: New IPO And A Leader In The Hypertension Drug Development Space. more_horizontal
By Market Watch
February 2, 2023
Mineralys Therapeutics sets IPO terms, which could value the HPV treatment company at nearly $600 million
Mineralys Therapeutics Inc. MLYS, has set terms for its initial public offering, in which the Pennsylvania-based hypertension treatment company looks more_horizontal
By 24/7 Wall Street
January 19, 2023
Hypertension Drug Maker Mineralys Therapeutics Prepares for $100 million IPO
A new biopharma play is on its way as hypertension medicine developer Mineralys Therapeutics prepares to come to market. more_horizontal